ReviewCurrent obesity reports2026
MASLD In Children - A Distinct Phenotype?
Review in Current obesity reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Childhood: From Disease Heterogeneity to Personalized Care.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewMetabolic dysfunction-associated steatotic liver disease (MASLD) represents a pattern shift in the classification and understanding of fatty liver disease in adults as well as children, overtaking the previous concept of non-alcoholic fatty liver disease (NAFLD). The adoption of MASLD places a central role of metabolic dysregulation, aligning with the diagnosis and clinical features with underlying cardiometabolic risk factors. Pediatric MASLD requires important focus due to its rising prevalence almost affecting up to 14% of children globally, and over 1/3 of children with obesity because of its distinct pathophysiological, histological, and clinical features compared to adult-onset disease. RECENT
findingsStudies reported that there is a major difference between pediatric and adult MASLD from epidemiology to genetic and metabolic factors to histopathology, and clinical expression. In children, periportal steatosis and fibrosis is prevalent, while in adults the centrilobular pattern is prevalent. Early-life exposures such as maternal obesity, rapid postnatal weight gain, and epigenetic factors amplify pediatric risk and shape the disease phenotype. Socioeconomic status, environmental factors, and sedentary behavior together elevate the pediatric incidence and severity. Due to unique histologic patterns, there are numerous problems associated with diagnosis and treatment. Also, a lack of non-invasive biomarkers and the need for individualized, pediatric-specific treatments that meet both medical and developmental needs should be focused on. Pediatric MASLD comprises a complex clinical and biological phenotype when compared to the adult MASLD in progression and metabolic context. This highlights an urgent need for pediatric-focused research, appropriate diagnostic strategies, and development-specific management protocols. Addressing these gaps is critical to manage the growing burden of MASLD among children worldwide and to improve long-term health outcomes as this population matures into adulthood.
Indexed as
Identifiers
41843228What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.